ISSN: 0300-8932 Factor de impacto 2023 7,2
Vol. 6. Núm. G.
Páginas 1G-2G (Septiembre 2006)

Tratamiento de las hiperlipemias en pacientes con riesgo cardiovascular elevado
Introducción

Pedro Mata¿

Opciones

Este artículo solo puede leerse en pdf
Bibliografía
[1.]
F.D.R. Hobbs, L. Erhardt.
Reassessing European Attitudes about Cardiovascular Treatment (REACT) survey: physician perceptions and attitudes towards cholesterol guidelines.
Eur Heart J, (2000), 21 pp. 477
[2.]
M.A. Nordlie, L. Wold, R. Kloner.
Genetic contributors toward increased risk for ischemic heart disease.
J Molec Cell Cardiol, (2005), 39 pp. 667-679
[3.]
T.P. Leren.
Cascade genetic screening for familial hypercholesterolemia.
Clin Genet, (2004), 5 pp. 7-11
[4.]
K. Mabuchi, J. Koizumi, M. Shimizu, R. Takeda.
Development of coronary heart disease in familial hypercholesterolemia.
Circulation, (1989), 79 pp. 225-232
[5.]
Z. Chen, R. Peto, R. Collins, S. MacMahon, J. Lu, W. Li.
Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations.
BMJ, (1991), 303 pp. 276-282
[6.]
Cholesterol Treatment Trialists’ (CTT) Collaborators.
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins.
Lancet, (2005), 366 pp. 1267-1278
[7.]
C.J. Murray, A.D. López.
Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study.
Lancet, (1997), 349 pp. 1498-1504
[8.]
S. Ulrich, A.D. Hingorani, J. Martin, P. Vallance.
What is the optimal age for starting lipid-lowering treatment? A mathematical model.
BMJ, (2000), 320 pp. 1134-1140
Copyright © 2006. Sociedad Española de Cardiología
¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?